QUINCE THERAPEUTICS Files 8-K Flagging Listing Rule Issue
The biotech filed an Item 3.01 disclosure with the SEC covering a delisting notice or failure to meet a continued listing standard, dated August 31, 2026.
Quince Therapeutics (QNCX) has filed a Form 8-K with the U.S. Securities and Exchange Commission under Item 3.01, the disclosure category reserved for a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The filing carries an event date of August 31, 2026 and was published on the SEC's EDGAR system on September 4, 2026.
Item 3.01 is used when a listed company receives notice from its exchange that it no longer meets a continued listing requirement, when the exchange moves to delist its securities, or when the company itself decides to transfer or withdraw a listing. The index of the submission does not spell out which of those situations applies here; that detail sits in the body of the 8-K document itself.
Quince Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California, classified by the SEC under SIC code 2836, biological products. Its shares trade under file number 001-38890.
For shareholders, an Item 3.01 filing is one of the more consequential routine disclosure categories, because it bears directly on where and whether a company's stock continues to trade. Small-cap biotechs most commonly land in this category over minimum bid price or stockholders' equity requirements, though the specific trigger in this case is not identified in the filing index.
Companies that receive a deficiency notice are typically granted a compliance period by the exchange to regain standing, and may request a hearing or pursue remedies such as a reverse stock split. Any such terms would be laid out in the full text of the 8-K.
This is a factual summary of a public filing or press release, not investment advice. Verify all figures against the source before acting on them.
